{"id":80098,"date":"2026-07-09T21:13:29","date_gmt":"2026-07-09T21:13:29","guid":{"rendered":"https:\/\/www.europesays.com\/britain\/80098\/"},"modified":"2026-07-09T21:13:29","modified_gmt":"2026-07-09T21:13:29","slug":"astrazenecas-stock-drops-on-wainuas-setback-in-attr-cm-study","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/britain\/80098\/","title":{"rendered":"AstraZeneca’s Stock Drops on Wainua’s Setback in ATTR-CM Study"},"content":{"rendered":"\n

Shares of AstraZeneca AZN fell nearly 8% in pre-market trading today after the company announced the failure of a phase III study evaluating Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). The company is co-developing this drug with Ionis Pharmaceuticals IONS, whose stock also slumped 19% following the announcement. <\/p>\n

The late-stage study, called CARDIO-TTRansform, failed to meet its primary endpoint of the composite outcome of cardiovascular (CV) mortality and recurrent CV clinical events. Although the drug was well tolerated in study participants over a 140-week treatment period, adding Wainua to the standard of care did not demonstrate a statistically significant benefit compared to placebo. <\/p>\n

The CARDIO-TTRansform study outcome comes as a surprise, as investors were expecting positive results. Wainua is already approved for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN), a condition in which misfolded transthyretin (TTR) protein deposits damage peripheral nerves. <\/p>\n

ATTR-CM is caused by the same misfolded TTR protein but primarily affects the heart, where amyloid deposits accumulate in the heart muscle, leading to progressive CV disease. Success in ATTR-CM was expected to significantly expand Wainua’s commercial opportunity, as the ATTR-CM market is considerably larger than the ATTRv-PN market. <\/p>\n

Both companies plan to analyze the full data set to better understand the results and intend to present the findings at the European Society of Cardiology (ESC) Congress next month. <\/p>\n

AZN Stock Performance <\/p>\n

Shares of AstraZeneca have underperformed the industry\u00a0so far this year, as seen in the chart below. <\/p>\n

\"Zacks<\/a> Zacks Investment Research <\/p>\n

Image Source: Zacks Investment Research <\/p>\n

Rivals Rally on AZN’s Setback <\/p>\n

Following AstraZeneca\/Ionis’ update, shares of Alnylam Pharmaceuticals ALNY and BridgeBio Pharma BBIO rose about 18% and 11%, respectively, in pre-market trading on Thursday. With Wainua failing to meet the primary endpoint in the CARDIO-TTRansform study, AstraZeneca’s entry into the ATTR-CM market now faces uncertainty. Investors appear to view the setback as strengthening the near-term competitive position of ALNY and BBIO. <\/p>\n

BridgeBio’s Attruby was approved by the FDA for ATTR-CM in 2024, while Alnylam’s Amvuttra received a label expansion for the indication last year. Both companies are well positioned in the rapidly growing ATTR-CM market, where effective disease-modifying therapies remain in high demand. <\/p>\n

While Amvuttra was initially approved for the treatment of ATTRv-PN, its label expansion into ATTR-CM significantly broadened the drug’s commercial opportunity. The expanded approval helped Amvuttra achieve blockbuster status, with sales surging 138% year over year to $2.31 billion in 2025, underscoring the sizable commercial potential of the ATTR-CM market. Meanwhile, BridgeBio generated $362.4 million in Attruby sales during the drug’s first full year on the market, reflecting the strong demand for therapies targeting the disease. <\/p>\n","protected":false},"excerpt":{"rendered":"Shares of AstraZeneca AZN fell nearly 8% in pre-market trading today after the company announced the failure of…\n","protected":false},"author":2,"featured_media":80099,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20662],"tags":[35544,11153,35510,30530,35565,35566,8703],"class_list":["post-80098","post","type-post","status-publish","format-standard","has-post-thumbnail","category-astrazeneca","tag-alnylam-pharmaceuticals","tag-astrazeneca","tag-attr-cm","tag-azn-stock","tag-pre-market-trading","tag-study-participants","tag-zacks-investment-research"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/116892087510867476","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/80098","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=80098"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/80098\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/80099"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=80098"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=80098"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=80098"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}